|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM302847006 |
| 003 |
DE-627 |
| 005 |
20231225111604.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2019 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1002/adma.201905271
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1009.xml
|
| 035 |
|
|
|a (DE-627)NLM302847006
|
| 035 |
|
|
|a (NLM)31680346
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Chang, Mengyu
|e verfasserin
|4 aut
|
| 245 |
1 |
2 |
|a A Multifunctional Cascade Bioreactor Based on Hollow-Structured Cu2 MoS4 for Synergetic Cancer Chemo-Dynamic Therapy/Starvation Therapy/Phototherapy/Immunotherapy with Remarkably Enhanced Efficacy
|
| 264 |
|
1 |
|c 2019
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 30.04.2020
|
| 500 |
|
|
|a Date Revised 30.09.2020
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a © 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
|
| 520 |
|
|
|a The unique tumor microenvironment (TME) facilitates cancer proliferation and metastasis, and it is hard to cure cancer completely via monotherapy. Herein, a multifunctional cascade bioreactor based on hollow mesoporous Cu2 MoS4 (CMS) loaded with glucose oxidase (GOx) is constructed for synergetic cancer therapy by chemo-dynamic therapy (CDT)/starvation therapy/phototherapy/immunotherapy. The CMS harboring multivalent elements (Cu1+/2+ , Mo4+/6+ ) exhibit Fenton-like, glutathione (GSH) peroxidase-like and catalase-like activity. Once internalized into the tumor, CMS could generate ·OH for CDT via Fenton-like reaction and deplete overexpressed GSH in TME to alleviate antioxidant capability of the tumors. Moreover, under hypoxia TME, the catalase-like CMS could react with endogenous H2 O2 to generate O2 for activating the catalyzed oxidation of glucose by GOx for starvation therapy accompanied with the regeneration of H2 O2 . The regenerated H2 O2 can devote to Fenton-like reaction for realizing GOx-catalysis-enhanced CDT. Meanwhile, the CMS under 1064 nm laser irradiation shows remarkable tumor-killing ability by phototherapy due to its excellent photothermal conversion efficiency (η = 63.3%) and cytotoxic superoxide anion (·O2 - ) generation performance. More importantly, the PEGylated CMSGOx-based synergistic therapy combined with checkpoint blockade therapy could elicit robust immune responses for both effectively ablating primary tumors and inhibiting cancer metastasis
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a PEGylated CMS@GOx
|
| 650 |
|
4 |
|a cancer metastasis inhibition
|
| 650 |
|
4 |
|a cascade reaction
|
| 650 |
|
4 |
|a immune system activation
|
| 650 |
|
4 |
|a synergistic therapy
|
| 650 |
|
7 |
|a Cu(2)MoS(4)
|2 NLM
|
| 650 |
|
7 |
|a Drug Carriers
|2 NLM
|
| 650 |
|
7 |
|a Copper
|2 NLM
|
| 650 |
|
7 |
|a 789U1901C5
|2 NLM
|
| 650 |
|
7 |
|a Molybdenum
|2 NLM
|
| 650 |
|
7 |
|a 81AH48963U
|2 NLM
|
| 650 |
|
7 |
|a Glucose Oxidase
|2 NLM
|
| 650 |
|
7 |
|a EC 1.1.3.4
|2 NLM
|
| 700 |
1 |
|
|a Wang, Man
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wang, Meifang
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Shu, Mengmeng
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ding, Binbin
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Li, Chunxia
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Pang, Maolin
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Cui, Shuzhong
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Hou, Zhiyao
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Lin, Jun
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Advanced materials (Deerfield Beach, Fla.)
|d 1998
|g 31(2019), 51 vom: 02. Dez., Seite e1905271
|w (DE-627)NLM098206397
|x 1521-4095
|7 nnns
|
| 773 |
1 |
8 |
|g volume:31
|g year:2019
|g number:51
|g day:02
|g month:12
|g pages:e1905271
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1002/adma.201905271
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 31
|j 2019
|e 51
|b 02
|c 12
|h e1905271
|